TELA Bio, Inc.

TELA Nasdaq SEC CIK 1561921
Follow TELA Bio Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $19M −8.4% vs same quarter last year
Net income −$9.3M −8.1% vs same quarter last year
EPS, diluted −$0.16 +15.8% vs same quarter last year
Operating cash flow −$8.7M −52% vs same quarter last year
Revenue by quarter
$17.6M
$18.5M
$20.2M
$20.7M
$20.9M
$19.1M
$19.3M
$19M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$50M$0$50M$100MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$80.3M−$38.8M
FY24$69.3M−$37.8M
FY23$58.5M−$46.7M
FY22$41.4M−$44.3M
FY21$29.5M−$33.3M
FY20$18.2M−$28.8M
FY19$15.4M−$22.4M
FY18$8.3M−$21.1M
FY17$4.2M−$21.3M
FY16--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−600%−400%−200%0%200%FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2567.7%−42%−48.3%
FY2467.1%−49.2%−54.5%
FY2368.6%−75.4%−79.9%
FY2265.3%−94.2%−106.9%
FY2163.9%−100%−112.9%
FY2061.7%−138.8%−158.1%
FY1960%−124.1%−145.2%
FY1835.6%−214.9%−254.9%
FY1759.6%−398.7%−502.6%
FY16---
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$28.7M
FY24−$42.6M
FY23−$41.5M
FY22−$41.6M
FY21−$31.1M
FY20−$24.6M
FY19−$25.7M
FY18−$20M
FY17−$16.5M
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • TELA Bio
  • Healthcare median
−600%−400%−200%0%FY17FY19FY21FY23FY25
Show the numbers
YearTELA BioHealthcare median
FY25−48.3%−30.6%
FY24−54.5%−47%
FY23−79.9%−58%
FY22−106.9%−80.4%
FY21−112.9%−71.8%
FY20−158.1%−62.2%
FY19−145.2%−46.2%
FY18−254.9%−49.6%
FY17−502.6%−45.9%
FY16-−36%